#GDMT plays a pivotal role in LV reverse remodeling (LVRR) in FMR and leads to reduction in severity and improved outcomes for both atrial and ventricular #FMR
Studies report 28% to 50% reduction in grade of #FMR from baseline in patients receiving optimal or maximally tolerated doses of #GDMT (including diuretics) in both ischemic #cardiomyopathy and non-ischemic CMP
In #HFrEF patients with ventricular FMR, it consists of #RAASi preferentially #ARNI, #BBs with most evidence available for #carvedilol, #MRA with clearer evidence for spironolactone, #SGLT2i, and when appropriate consideration of ivabradine, hydralazine, and vericiguat.
For patients with ischemic MR and #HFpEF, consideration for #revascularization and CAD medical treatment are appropriate.
Patients with #HFmrEF and ventricular FMR seem to derive benefit from similar regimen as #GDMT for HFrEF, with most evidence for #BBs, #ARNI/ #ARB, and #MRA
For Atrial #MR and #AF, restoration of sinus rhythm when feasible is advised, and RAASi Rx when concurrent indications exist
For patients with #HFpEF and either atrial or ventricular FMR, evidence for #GDMT ( ARNI/ARB + SGLT2i + MRA ) seems promising through their effect on LVRR
#Immunosuppressive therapy in virus-negative inflammatory CMP : 20-year follow-up of the #TIMIC trial
Immunosuppressive Tx of virus-negative inflammatory #CMP is associated to a persistent improvement of LV
function and better outcomes during long-term follow-up
#Immunosuppressive Tx promoted an improvement in cardiac function in 88% of the cases compared the placebo group
A persistent ⤴️ in the #LVEF is seen in long -term (up to 20 years) clinical outcomes of the whole cohort of 85 patients originally enrolled in the #TIMIC trial
Recurring virus-negative myocarditis responding to #immunosuppressive therapy
EKG showing LBBB (A) resolving after therapy (B)
(C and D) Echo apical view showing recovery of LV dysfunction from EF -28% ➡️ up to 51%
#MRAs were used in 37% of EMPEROR-Preserved study participants. MRA use was higher in those with a more congested clinical picture, with more HF🏥 within the past 12 months, worse HF symptoms, mildly reduced EF, higher NT-proBNP levels, and more use of loop diuretic agents
This expert consensus document from the #EACVI provides recommendations regarding how to determine elevated LV filling pressure in the setting of suspected #HFpEF and how to use multimodality imaging to determine specific aetiologies in patients with HFpEF @EACVIPresident
📌Mechanisms of LV diastolic dysfunction include impaired relaxation, attenuated restoring forces, and increased passive elastic stiffness that leads to elevated LV filling pressure
📌The presence of LV hypertrophy and dilated LA provides support for the #HFpEF diagnosis
Very insightful presentation by @JavedButler1 on New evidence from meta-analyses ‒ lessons to learn on the benefits of intravenous ferric carboxymaltose in HF